Charles River Laboratories Cash on Hand 2010-2024 | CRL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Charles River Laboratories cash on hand for 2024 was $0.195B, a 29.69% decline from 2023.
Charles River Laboratories cash on hand for 2023 was $0.277B, a 18.32% increase from 2022.
Charles River Laboratories cash on hand for 2022 was $0.234B, a 3.03% decline from 2021.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Charles River Laboratories cash on hand for 2024 was $0.195B, a 29.69% decline from 2023.
Charles River Laboratories cash on hand for 2023 was $0.277B, a 18.32% increase from 2022.
Charles River Laboratories cash on hand for 2022 was $0.234B, a 3.03% decline from 2021.

Related Stocks
Company Name	Market Cap
Danaher (DHR)	$148.1B
Elevance Health (ELV)	$90.8B
CVS Health (CVS)	$83.7B
Cencora (COR)	$47.6B
DiDi Global (DIDIY)	$23.1B
Natera (NTRA)	$22.8B
ICON (ICLR)	$15.8B
Doximity (DOCS)	$14.3B
BioMerieux (BMXMF)	$14.1B
Revvity (RVTY)	$14B
Viatris (VTRS)	$13B
Solventum (SOLV)	$12.8B
Avantor (AVTR)	$12B
CochLear (CHEOY)	$11.5B
Medpace Holdings (MEDP)	$10.5B
HealthEquity (HQY)	$9.9B
EUROFINS SCIENT (ERFSF)	$9.5B
Sonic Healthcare (SKHHY)	$8.8B
Amplifon S.p.A (AMFPF)	$6.2B
Bausch + Lomb (BLCO)	$5.7B
Organon (OGN)	$3.9B
Sotera Health (SHC)	$3.9B
BrightSpring Health Services (BTSG)	$3.6B
Surgery Partners (SGRY)	$3.3B
GeneDx Holdings (WGS)	$3.1B
Concentras Parent (CON)	$3B
Alignment Healthcare (ALHC)	$2.7B
Teladoc Health (TDOC)	$2.4B
Ardent Health Partners (ARDT)	$2.1B
Progyny (PGNY)	$2B